Mereo BioPharma Group plc
Mereo BioPharma Group plc (MREO) Stock Overview
Explore Mereo BioPharma Group plc’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
268.6M
P/E Ratio
-5.75
EPS (TTM)
$-0.35
ROE
-0.69%
MREO Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Mereo BioPharma Group plc (MREO) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 26.41, suggesting the stock is in an oversold condition. Our forecasting models predict significant price movements, with a 12-month target of N/A.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -5.75 and a market capitalization of 268.6M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Analyst Recommendations
Price Targets
Company Profile
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
Denise Vera Scots-Knight
36
One Cavendish Place, London
2019